|
|
6/8/2006 11:05:05 AM ET
SWISS MEDICA CONTINUES TO RECEIVE INTERNATIONAL ATTENTION FOR O24 FIBROMYALGIA™
FOR IMMEDIATE RELEASE
Stock Symbol: OTC BB: SWME
June 8, 2006
Toronto, Canada – Swiss Medica, Inc. (OTC BB: SWME) announced today that international recognition
continues to grow for its patented, all natural and clinically tested product O24 Fibromyalgia™, with official
approval by the Fibromyalgia Support Group Surrey & Sussex in the United Kingdom.
O24 Fibromyalgia™ is the first clinically-tested product available in national pharmacies to help patients fight the
intense, debilitating pain caused by Fibromyalgia.
O24 Fibromyalgia™ was launched in late 2005 in the United States when the product was awarded the first ever
Seal of Approval from the California-based National Fibromyalgia Association (NFA). Upwards of 11 million
Americans suffer from this debilitating chronic ailment.
Similar recognition for O24 Fibromyalgia™ was received by the FM-CFS (Fibromyalgia and Chronic Fatigue
Syndrome) of Canada late last year, the group representing Fibromyalgia patients in Canada.
In early 2005, Swiss Medica conducted research which involved a double blind clinical trial by Dr. Gordon Ko
(Head, Fibromyalgia Clinic) and Dr. David Berbrayer (Head, Dept. Rehabilitation Medicine) at Sunnybrook &
Women's Health Sciences Centre (University of Toronto in Ontario, Canada). This clinical trial demonstrated that
88% of the patients using the O24 Fibromyalgia™ product reported mild to markedly better improvement on the
7-point Lanier rating scale, versus only 7% who used the placebo. A copy of Dr. Ko’s study is available for
review at www.O24zone.com/Clinicals.html.
Swiss Medica also announced today that Raghu Kilambi, Swiss Medica’s Co-Founder and CEO, has recently
purchased 575,000 Class A common shares of Swiss Medica on the open market and through the exercise of
stock options. Mr. Kilambi has purchased, since May 30, 425,000 shares of Swiss Medica common shares on the
open market and has purchased 150,000 shares by exercising stock options. Details of these purchases are
included in Form 4’s that have been filed with the S.E.C. and accessible via the investor section of www.
swissmedica.com.
Mr. Kilambi stated “I continue to believe that our shares are undervalued based on the market potential of our
products. This insider buying reflects my belief in Swiss Medica’s strategy, our products and our team.”
About Swiss Medica, Inc.
Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be
a world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.
Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by
healthcare professionals and athletes in the United States, Canada and in Europe. O24™ is widely available
throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit
www.O24zone.com, for ordering details and store locators for the nearest pharmacy.
Swiss Medica launched the patented O24 Fibromyalgia™ pain reliever (US Patent #6,444,238B1) over-the-
counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently
awarded O24 Fibromyalgia™ their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the
long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of
the patients who used O24 Fibromyalgia™ reported mild to markedly better improvement, versus only 7 per cent
who used the placebo. Customers can visit www.O24zone.com for information on O24 Fibromyalgia™ and to
order the product online.
Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS
Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce
changes in mood and appetite that women experience during the premenstrual period. Customers can also visit:
www.pmsescape.com for additional information and ordering details.
Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the
United States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
transactions being contemplated, risks related to international sales and potential foreign currency exchange
fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
periodic reports filed with the United States Securities and Exchange Commission and other regulatory
authorities.
For more information, please contact:
Swiss Medica, Inc.
Investor Relations Contact:
David Jones
1-866-485-4243
djones@swissmedica.com
|
|
